Overview
Lanicemine has been used in trials studying the treatment and basic science of Depression, Major Depressive Disorder, and Treatment Resistant Major Depressive Disorder.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
Lanicemine (DB11889): A Comprehensive Pharmacological and Clinical Development Profile
1. Introduction to Lanicemine
1.1. Overview and Chemical Properties
Lanicemine is an investigational small molecule drug, identified by the DrugBank Accession Number DB11889, which has been the subject of numerous clinical trials, primarily focusing on its potential as a treatment for depressive disorders.[1] Its Chemical Abstracts Service (CAS) Registry Number is 153322-05-5 for the free base form.[2]
Lanicemine is known by several synonyms, reflecting its journey through different stages of development and by various research groups. These include AZD6765, its development code under AstraZeneca; AR-R 15896AR, an earlier development designation; (αS)-phenyl-2-pyridineethanamine, its chemical name; and BHV-5500, the code used by Biohaven Pharmaceuticals.[1] The dihydrochloride salt form of Lanicemine is also documented, with CAS Number 153322-06-6.[19]
The molecular formula for the free base of Lanicemine is C13H14N2.[1] Its average molecular weight is approximately 198.269 g/mol, often rounded to 198.27 g/mol.[1] The dihydrochloride salt form has a molecular weight of 271.19 g/mol.[19]
In its physical form, Lanicemine free base has been described as a neat oil.[2] The dihydrochloride salt is typically an off-white to light yellow solid.[19] Regarding solubility, the free base form is soluble in organic solvents such as ethanol, dimethyl sulfoxide (DMSO), and dimethylformamide. The dihydrochloride salt exhibits good solubility in DMSO and water, with aqueous solubility reported as ≥100 mg/mL.[2] Specific solubility data indicates approximately 20 mg/mL in ethanol, 30 mg/mL in DMSO, and 5 mg/mL in dimethylformamide for the free base, and ≥100 mg/mL in water and 240 mg/mL in DMSO (requiring sonication) for the dihydrochloride salt.[2]
Table 1: Lanicemine Identifiers and Basic Properties
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2017/05/25 | Phase 1 | Completed | |||
2010/05/26 | Phase 1 | Terminated | |||
2010/02/17 | Phase 1 | Completed | |||
2010/01/12 | Phase 1 | Completed | |||
2009/09/30 | Phase 2 | Completed | |||
2009/08/21 | Phase 1 | Withdrawn | |||
2008/11/05 | Phase 1 | Completed | |||
2008/10/29 | Phase 2 | Completed | |||
2007/06/26 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
No Health Canada approvals found for this drug. |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.